__NUXT_JSONP__("/drugs/Ziv-Aflibercept", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:"ZALTRAP",indication:"1 INDICATIONS AND USAGE ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. ZALTRAP, a vascular endothelial growth factor inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. ( 1 )",manufacturer:"sanofi-aventis U.S. LLC",splSetId:"f6725df6-50ee-4b0a-b900-d02ba634395d"},{brand:"EYLEA",indication:"1 INDICATIONS AND USAGE EYLEA is indicated for the treatment of: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)",manufacturer:"Regeneron Pharmaceuticals, Inc.",splSetId:"f96cfd69-da34-41ee-90a9-610a4655cd1c"}],id:a,nciThesaurus:{casRegistry:"862111-32-8",chebiId:b,chemicalFormula:b,definition:"A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.",fdaUniiCode:"15C2VL427D",identifier:"C2682",preferredName:a,semanticType:"Immunologic Factor",subclassOf:["C163758","C1971"],synonyms:["AFLIBERCEPT","AVE0005","Aflibercept","Eylea","VEGF Trap","VEGF Trap R1R2","VEGF-Trap","Vascular Endothelial Growth Factor Trap","Zaltrap",a,"aflibercept","vascular endothelial growth factor trap"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FZiv-Aflibercept",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Ziv-Aflibercept","","2021-10-30T13:38:19.323Z")));